Advancing Innovative Immune-Oncology Technologies

We are a biopharmaceutical company focused on advancing proprietary technology platforms across multiple high-value cancer indications.

More About Us

Targeting Neutrophil Extracellular Traps (NETs)

NETs are a driver of cancer progression and metastasis and can also contribute to resistance to chemotherapy, checkpoint inhibitors and radiotherapy.

DNase I Oncology Platform

Oncology platform aimed at improving cancer therapies with the opportunity to address multiple oncology indications, including pancreatic cancer and other solid tumors.

Pipeline

Stock InformationView Detailed Stock Information

Nasdaq: XBIO Xenetic Biosciences, Inc.
Price
Change
Volume
Day Range
52 Week Range

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today